Joined Bio

Cover Block

Field	Value
Name	Joined Bio
Tagline	Platform connecting patients with researchers for sharing biospecimens, health data, and insights to accelerate medical breakthroughs
Headquarters	Lexington, Massachusetts, United States
Founded	2024
Stage	Seed
Business Model	Marketplace
Industry	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale

Links

• Website: https://joined.bio/
• LinkedIn: https://www.linkedin.com/company/joined-bio
• BioSample Connect (subsidiary): https://biosampleconnect.joined.bio/
• DNAsimple (subsidiary): https://www.dnasimple.org/

Executive Summary

Joined Bio is a Lexington, Massachusetts health technology company building a two-sided marketplace that pays individuals to contribute health data, biospecimens, and survey responses to life-science researchers, with participant compensation reportedly reaching up to $250 per study [Joined Bio, October 2025]. The company emerged publicly in late 2025 with a launch announcement framing three integrated capabilities: secure ingestion of electronic medical record data, profile-based study matching, and nationwide in-home biospecimen collection [Joined Bio, October 2025]. In a span of roughly eight months, Joined Bio executed two acquisitions, BioSample Connect for procurement and supplier infrastructure [Joined Bio] and DNAsimple for participant-direct genetic sample collection [Crunchbase], consolidating three businesses into one patient-powered research platform. The strategic logic is to be the only operator that pairs engaged participants with EMR-linked datasets and at-home logistics in a single workflow, a stack that today is typically assembled across multiple vendors [Joined Bio, November 2025]. Funding has not been publicly disclosed, and named founders or institutional investors are not surfaced in the cited sources. The team includes Bill Arteca and Jill Mullan in visible operating roles per their LinkedIn profiles [LinkedIn].

Data Accuracy: YELLOW -- Cross-checked against Joined Bio press releases, Crunchbase acquisition record, and LinkedIn profiles; capitalization remains undisclosed.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	Marketplace
Industry / Vertical	Healthtech, clinical research enablement
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale

How the Company Got Here

Joined Bio was founded in 2024 and is headquartered in Lexington, Massachusetts, positioning itself as a patient-powered research marketplace that intermediates between life-science researchers and individuals willing to contribute data and biological material [Joined Bio, October 2025]. The company's public narrative centers on a structural inefficiency in clinical and translational research: the slow, fragmented process of sourcing qualified participants and matched biospecimens. Its solution combines a consumer-facing participant platform with researcher-facing procurement tools inherited from its acquired subsidiaries.

The company's milestone sequence is unusually compressed for a seed-stage business. In early 2025, Joined Bio acquired BioSample Connect, a specialized provider of biospecimen collection and management services [Joined Bio]. On November 3, 2025, Joined Bio announced the acquisition of DNAsimple, a participant-direct genetic sample collection business [Joined Bio, November 2025]. The DNAsimple transaction is recorded in Crunchbase as an acquisition without disclosed deal terms [Crunchbase]. The public platform launch announcement followed on October 29, 2025 from Lexington [Joined Bio, October 2025].

Legal entity details, total capital raised, and the founding team roster are not disclosed in the captured sources. Bill Arteca and Jill Mullan appear in operating roles based on their LinkedIn profiles, with Mullan posting publicly about the BioSample Connect acquisition [LinkedIn]. The company's editorial output, including a published essay on the 23andMe data exposure incident, signals a deliberate positioning around participant trust and data governance as competitive features [Joined Bio].

Data Accuracy: YELLOW -- Confirmed via company press releases and Crunchbase acquisition record; founder identities and capitalization not independently verified.

Product and Technology

The Joined Bio product is a participant-facing platform that onboards individuals, ingests their electronic medical record data, and matches them to research studies against their health profile [Joined Bio]. Participation modes span four tiers: sharing health data, completing surveys, providing biospecimens, and enrolling in clinical trials, with compensation reportedly reaching up to $250 per study [Joined Bio, October 2025]. The company describes three core capabilities at launch: secure integration of comprehensive EMR data, intelligent participation matching, and nationwide in-home collection [Joined Bio, October 2025].

On the researcher and supplier side, the BioSample Connect subsidiary continues to operate as a procurement channel, serving medical clinics, hospitals, and biospecimen suppliers with sales, marketing, and business growth services [Joined Bio]. The DNAsimple acquisition adds a participant-direct genetic sample collection workflow, now folded into the Joined Bio platform [Joined Bio, November 2025]. The combined offering is the only platform pairing engaged patients, deep EMR data, and professional at-home collection in a single execution layer [Joined Bio, November 2025].

The underlying technology stack is not described in detail in public materials. EMR integration vendors, identity verification providers, payment rails for participant compensation, and the logistics partner powering at-home collection are not named in the captured sources. The company has published positioning content on health data security in the wake of the 23andMe incident, indicating that data governance, retention policy, and participant control are treated as product surface area [Joined Bio].

Data Accuracy: YELLOW -- Product capabilities corroborated by company website, launch press release, and subsidiary properties; technical stack not publicly available.

Market Research and Opportunity

The market Joined Bio addresses sits at the intersection of clinical trial enablement, biospecimen procurement, and the broader real-world data economy. Participant recruitment and biospecimen sourcing are persistent bottlenecks in translational research [Joined Bio, October 2025]. The structural problem is that studies are routinely delayed because qualified participants with the right phenotype, genotype, or condition history cannot be identified and consented at the speed researchers need them.

Adjacent and substitute markets that bound the opportunity include traditional clinical research organizations, central biorepositories, decentralized clinical trial platforms, and consumer genetics companies that have historically monetized de-identified data through pharma partnerships. The Joined Bio editorial titled "The Billion-Dollar Health Data Economy (That Patients Don't Share In)" frames the company's positioning thesis: that value generated from health data has accrued to platforms and aggregators rather than to the individuals who supplied the data [Joined Bio].

Demand-side tailwinds include the continued shift to decentralized and hybrid trial designs, regulatory momentum around real-world evidence acceptability at the FDA, and pharma sponsor pressure to compress trial timelines. Macro and regulatory headwinds include HIPAA and state genetic privacy laws (notably the GINA framework and California's CCPA/CPRA regime), and the 23andMe security incident the company references publicly [Joined Bio] has heightened both regulator and consumer scrutiny of consumer-facing health data businesses.

Metric	Value
Participant compensation per study	up to $250
Confirmed acquisitions completed within ~8 months	2

Data Accuracy: ORANGE -- Market framing supported by company narrative; no third-party TAM source captured.

Competitive Landscape

Joined Bio is positioned as a vertically integrated patient-powered research marketplace. The segment-by-segment map has three layers. The first is patient registries and recruitment platforms, populated by businesses that match individuals to studies but typically do not handle biospecimen logistics [Joined Bio, October 2025]. The second is biospecimen procurement, historically served by central biobanks, hospital tissue banks, and specialized commercial brokers; BioSample Connect operated in this layer pre-acquisition [Joined Bio]. The third is consumer genetic data businesses that monetize de-identified datasets through research partnerships; Joined Bio's published commentary on the 23andMe incident suggests the company sees that adjacency as both a cautionary tale and a positioning contrast on participant control [Joined Bio].

Where the company has a defensible edge today is in the integration itself. Few operators combine an EMR-linked participant pool, prospective and banked biospecimen procurement, and at-home collection logistics under one workflow [Joined Bio, November 2025]. That integration is durable to the extent that participant relationships and EMR consents compound over time and are difficult to replicate quickly. It is perishable to the extent that any one layer can be commoditized by a focused specialist with deeper capital, and to the extent that pharma sponsors prefer to multi-source rather than concentrate dependency.

Data Accuracy: ORANGE -- Competitive set inferred from category structure; no direct competitors named in captured sources.

Opportunity

If Joined Bio executes, the prize is becoming the default execution layer for biospecimen-and-EMR research studies in North America. The company's own framing, that it is the only platform executing complete biospecimen research studies with engaged patients, deep EMR data, and professional at-home collection [Joined Bio, November 2025], is a coherent claim. The three component capabilities have all been assembled (organically for matching and EMR, via BioSample Connect for procurement, via DNAsimple for direct-to-participant genetic collection) and the integration work is what now stands between the company and category leadership [Joined Bio, October 2025].

Scenario	What happens	Catalyst	Why it's plausible
Pharma sponsor standard	Joined Bio becomes a preferred vendor for two or three top-20 pharma sponsors	A named master services agreement	The integrated stack addresses a persistent bottleneck [Joined Bio, October 2025]
Roll-up of patient-direct collection	Continued acquisition of niche participant-direct collection brands	Additional tuck-ins	Two acquisitions executed within roughly eight months suggest an active M&A motion
Real-world evidence platform	The participant base becomes a longitudinal cohort sold for repeated study access	Cohort reaches a size where pharma will pay for standing access	EMR integration plus participant compensation create the economic incentive for repeat participation [Joined Bio, October 2025]

Data Accuracy: YELLOW -- Scenarios constructed from company-stated capabilities and category comparables; no third-party valuation source cited.

Sources

1. [Joined Bio] Home | https://joined.bio/
2. [Joined Bio, October 2025] Joined Bio Launches Platform Empowering Participants to Share Biospecimens, Health Data, and Insights for Breakthrough Research | https://joined.bio/news/joined-bio-lunches-platform-empowering-participants-to-share-biospecimens-health-data-and-insights-for-breakthrough-research/
3. [Joined Bio, November 2025] Joined Bio Acquires DNAsimple to Create Industry's Most Comprehensive Patient-Powered Research Platform | https://joined.bio/news/joined-bio-acquires-dnasimple-to-create-industrys-most-comprehensive-patient-powered-research-platform/
4. [Joined Bio] BioSample Connect | https://biosampleconnect.joined.bio/
5. [Joined Bio] Our Procurement Model, BioSample Connect | https://biosampleconnect.joined.bio/procurement_model
6. [Joined Bio] About Us, BioSample Connect | https://biosampleconnect.joined.bio/about-us
7. [Joined Bio] Joined Bio Acquires BioSample Connect, Accelerating Growth of its Patient-Centered Research Marketplace | https://joined.bio/news/joined-bio-acquires-biosample-connect-accelerating-growth-of-its-patient-centered-research-marketplace/
8. [Joined Bio] Why Health Data Is Secure With Joined Bio: Beyond the 23andMe Lesson | https://joined.bio/news/beyond-the-23andme-lesson
9. [Joined Bio] The Billion-Dollar Health Data Economy (That Patients Don't Share In) | https://joined.bio/news/the-billion-dollar-health-data-economy-that-patients-dont-share-in/
10. [ZoomInfo] Joined Bio Overview | https://www.zoominfo.com/c/joined-bio/1340941263
11. [Crunchbase] Acquisition: DNA Simple acquired by Joined Bio | https://www.crunchbase.com/acquisition/joined-bio-acquires-dna-simple--f5650f81
12. [DNAsimple] DNAsimple, Now a part of Joined Bio | https://www.dnasimple.org/
13. [LinkedIn] Bill Arteca, Joined Bio | https://www.linkedin.com/in/bill-arteca/
14. [LinkedIn] Jill Mullan, Joined Bio | https://www.linkedin.com/in/jmullan/
15. [LinkedIn] Joined Bio Company Page | https://www.linkedin.com/company/joined-bio